Case Reports
Early Access
https://doi.org/10.4081/dr.2026.10522

Successful use of dupilumab in a patient with atopic dermatitis and autosomal dominant polycystic kidney disease: a case report

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 4 June 2026
131
Views
24
Downloads
Atopic dermatitis, autosomal dominant polycystic kidney disease, dupilumab, monoclonal antibody therapy, interleukin-4, interleukin-13

Authors

Arlind Kalaja
arlind.kalaja@unipr.it
Dermatology Department, Ospedale Maggiore di Parma, Italy.
Barbara Cocuroccia
Dermatology Department, Istituto Dermopatico dell’Immacolata IRCCS, Rome, Italy.
Donatella Sordi
Dermatology Department, Istituto Dermopatico dell’Immacolata IRCCS, Rome, Italy.
Anna Dattolo
Laboratory of Experimental Immunology, Istituto Dermopatico dell’Immacolata IRCCS, Rome, Italy.
Sabatino Pallotta
Dermatology Department, Istituto Dermopatico dell’Immacolata IRCCS, Rome, Italy.
Ignazio Stanganelli
Dermatology Department, Ospedale Maggiore di Parma, Italy.
Filomena Russo
Dermatology Department, Istituto Dermopatico dell’Immacolata IRCCS, Rome, Italy.

This case report explores the management of a young female with both atopic dermatitis (AD) and autosomal dominant polycystic kidney disease (ADPKD), treated with dupilumab. Although these conditions are distinct, their coexistence poses clinical challenges. Dupilumab, a monoclonal antibody targeting interleukin (IL)-4 and IL-13, is effective for moderate-to-severe AD. This case highlights the safety and efficacy of dupilumab in ADPKD patients, with no adverse renal effects observed.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
1. Foti C, Romita P, Ambrogio F, et al. Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases. Life (Basel) 2022;12:2002.
2. Yang YQ, Chen H, Qiu LR, Zhu RF. Case Report: The Application of Dupilumab in Atopic Dermatitis Children Complicated With Nephrotic Syndrome. Front Med (Lausanne) 2022;9:813313.
3. Yamamoto M, Kawase Y, Nakajima E, et al. Exacerbation of IgA nephropathy in a patient receiving dupilumab. JAAD Case Rep 2022;21:150-3.
4. Kha C, Raji K, Chisolm S. Treatment of Atopic Dermatitis With Dupilumab in a Renal Transplant Patient. Dermatitis 2020;31:e17-8.
5. Tanczosova M, Arenberger P, Rychlik I, et al. Improvement of atopic dermatitis and IgA nephropathy in a patient treated by dupilumab. Dermatol Ther 2021;34:e14708.
6. Zhai LL, Savage KT, Qiu CC, et al. Chronic Pruritus Responding to Dupilumab-A Case Series. Medicines (Basel) 2019;6:72.
7. Varma A, Tassavor M, Levitt J. The utility of dupilumab for use in the pediatric population. JAAD Case Rep 2019;5:943-4.
8. Lucca MB, Recuero JK, Lorenzini D, Weber MB. Dupilumab for atopic dermatitis in children with idiopathic nephrotic syndrome treated with cyclosporin: a report of two cases. Australas J Dermatol 2024;65:292-4.

How to Cite



1.
Kalaja A, Cocuroccia B, Sordi D, Dattolo A, Pallotta S, Stanganelli I, et al. Successful use of dupilumab in a patient with atopic dermatitis and autosomal dominant polycystic kidney disease: a case report. Dermatol Reports [Internet]. 2026 Jun. 4 [cited 2026 Jun. 8];. Available from: https://journals.pagepress.net/dr/article/view/10522
Copyright (c) 2026 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.